Morgan Stanley Repligen Corp Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Repligen Corp stock. As of the latest transaction made, Morgan Stanley holds 525,108 shares of RGEN stock, worth $71.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

525,108

Previous 596,497 11.97%

Holding current value

$71.9 Million

Previous $88.8 Million 14.85%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$123.41 - $160.92 $8.81 Million - $11.5 Million	-71,389 Reduced 11.97%	525,108 $75.6 Million
Q3 2024 Nov 14, 2024	BUY	$119.79 - $167.35 $2.5 Million - $3.49 Million	20,880 Added 3.63%	596,497 $88.8 Million
Q2 2024 Oct 17, 2024	BUY	$120.0 - $182.95 $3.73 Million - $5.68 Million	31,061 Added 5.7%	575,617 $72.6 Million
Q2 2024 Aug 14, 2024	BUY	$120.0 - $182.95 $3.73 Million - $5.68 Million	31,061 Added 5.7%	575,617 $72.6 Million
Q1 2024 Oct 17, 2024	SELL	$170.78 - $208.42 $5.3 Million - $6.47 Million	-31,061 Reduced 5.4%	544,556 $100 Million
Q1 2024 Aug 16, 2024	BUY	$170.78 - $208.42 $601,828 - $734,472	3,524 Added 0.65%	544,556 $100 Million
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $601,828 - $734,472	3,524 Added 0.65%	544,556 $100 Million
Q4 2023 Aug 16, 2024	SELL	$114.17 - $185.35 $3.95 Million - $6.41 Million	-34,585 Reduced 6.01%	541,032 $97.3 Million
Q4 2023 Feb 13, 2024	BUY	$114.17 - $185.35 $6.35 Million - $10.3 Million	55,632 Added 11.46%	541,032 $97.3 Million
Q3 2023 Nov 15, 2023	BUY	$138.78 - $176.51 $3.85 Million - $4.9 Million	27,747 Added 6.06%	485,400 $77.2 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $12.7 Million - $16.5 Million	91,506 Added 24.99%	457,653 $64.7 Million
Q1 2023 May 15, 2023	SELL	$154.26 - $198.1 $7.59 Million - $9.74 Million	-49,171 Reduced 11.84%	366,147 $61.6 Million
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $24.6 Million - $33.5 Million	151,754 Added 57.58%	415,318 $70.3 Million
Q3 2022 Nov 14, 2022	BUY	$160.42 - $256.21 $6.31 Million - $10.1 Million	39,307 Added 17.53%	263,564 $49.3 Million
Q2 2022 Oct 27, 2022	BUY	$140.68 - $188.02 $11.4 Million - $15.2 Million	80,889 Added 56.42%	224,257 $36.4 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $11.4 Million - $15.2 Million	80,889 Added 56.42%	224,257 $36.4 Million
Q1 2022 Oct 27, 2022	SELL	$161.19 - $257.96 $13 Million - $20.9 Million	-80,889 Reduced 36.07%	143,368 $27 Million
Q1 2022 May 13, 2022	BUY	$161.19 - $257.96 $2.85 Million - $4.57 Million	17,711 Added 14.09%	143,368 $27 Million
Q4 2021 Feb 14, 2022	BUY	$247.59 - $304.47 $9.04 Million - $11.1 Million	36,511 Added 40.96%	125,657 $33.3 Million
Q3 2021 Nov 15, 2021	BUY	$194.77 - $324.21 $17.4 Million - $28.9 Million	89,146 New	89,146 $25.8 Million

Others Institutions Holding RGEN

# of Institutions

482

Shares Held

56.3M

Call Options Held

251K

Put Options Held

458K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.6B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account